News | October 02, 2024
Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The inspection concluded with the issuance of a form 483 with five observations
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Subscribe To Our Newsletter & Stay Updated
